5ht1 receptor agonists and metoclopramide for the treatment...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/404 (2006.01) A61K 31/16 (2006.01) A61K 31/166 (2006.01) A61K 31/40 (2006.01) A61K 31/4045 (2006.01) A61K 31/41 (2006.01) A61K 31/4196 (2006.01) A61K 31/42 (2006.01) A61K 31/445 (2006.01) A61K 31/454 (2006.01) A61K 31/495 (2006.01) A61K 45/00 (2006.01) A61P 25/06 (2006.01) C07D 209/14 (2006.01) C07D 401/00 (2006.01) C07D 403/06 (2006.01)

Patent

CA 2348543

The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT1 receptor agonist, and particularly eletriptan, in combination with metoclopramide. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1 receptor agonist and metoclopramide.

Procédé de traitement de la migraine chez un mammifère, dont un être humain, qui consiste à administrer à ce mammifère un agoniste de récepteur 5HT¿1?, en particulier de l'élétriptan, en combinaison avec du métoclopramide. La présente invention concerne également des compositions pharmaceutiques contenant un excipient acceptable sur le plan pharmaceutique, un agoniste de récepteur 5HT¿1? et du métoclopramide.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

5ht1 receptor agonists and metoclopramide for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5ht1 receptor agonists and metoclopramide for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5ht1 receptor agonists and metoclopramide for the treatment... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1724519

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.